SCHEMBL3440231

SCHEMBL3440231

O=C1c2ccccc2C(=O)N1C1CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.49
ALDH1A1 P00352 2/20 0.49
TSHR P16473 2/20 0.49
CHRM2 P08172 1/20 0.49
OPRM1 P35372 1/20 0.49
DDB1 Q16531 1/20 0.49
CRBN Q96SW2 1/20 0.49
IKZF3 Q9UKT9 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
HTR2B P41595 4/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
TMEM97 Q5BJF2 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
HTR2C P28335 4/20 0.46
HTR2A P28223 3/20 0.46
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31352052 1.00 CYP1A2 (0.49) CYP1A2ALDH1A1TSHRCHRM2OPRM1
Hydrochloric Acid SCHEMBL3195312 0.98 CYP1A2 (0.47) CYP1A2ALDH1A1TSHRCHRM2OPRM1
SCHEMBL29585627 0.89 HTR2B (0.58) CYP1A2ALDH1A1TSHRCHRM2OPRM1
SCHEMBL31238892 0.89 HTR2B (0.58) CYP1A2ALDH1A1TSHRCHRM2OPRM1
SCHEMBL24424025 0.89 HTR2B (0.58) CYP1A2ALDH1A1TSHRCHRM2OPRM1
Hydrochloric Acid SCHEMBL5381370 0.87 HTR2B (0.57) CYP1A2ALDH1A1TSHRCHRM2OPRM1
Hydrochloric Acid SCHEMBL8828239 0.87 HTR2B (0.57) CYP1A2ALDH1A1TSHRCHRM2OPRM1
Hydrochloric Acid SCHEMBL30032402 0.87 CYP1A2 (0.42) CYP1A2ALDH1A1TSHRCHRM2OPRM1
SCHEMBL2665681 0.86 L3MBTL1 (0.54) CYP1A2ALDH1A1TSHRCHRM2OPRM1
SCHEMBL9625796 0.86 L3MBTL1 (0.54) CYP1A2ALDH1A1TSHRCHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3147283-B1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR XA INHIBITOR NORTH CHINA PHARMACEUTICAL COMPANY LTD (CN) 2022-08-17 EP disclosed
US-9938272-B2 Hydrazine compound as blood coagulation factor Xa inhibitor NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) 2018-04-10 US disclosed
US-9938272-B2 Hydrazine compound as blood coagulation factor Xa inhibitor NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) 2018-04-10 US disclosed
US-20170152259-A1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) 2017-06-01 US disclosed
US-20170152259-A1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) 2017-06-01 US disclosed
EP-3147283-A1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR North China Pharmaceutical Company., Ltd. (CN) 2017-03-29 EP disclosed
EP-3147283-A1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR North China Pharmaceutical Company., Ltd. (CN) 2017-03-29 EP disclosed
US-9533979-B2 Amino-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2017-01-03 US disclosed
WO-2015176625-A1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR 南京明德新药研发股份有限公司 2015-11-26 WO disclosed
EP-2188251-B1 ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY BOEHRINGER INGELHEIM INT (DE) 2015-04-29 EP disclosed
WO-2008022945-A1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 WO disclosed
US-20050119250-A1 Antiproliferative agents JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-02 US disclosed
EP-1485370-A1 AMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-15 EP disclosed
WO-2003076430-A1 AMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2003-09-18 WO disclosed
EP-0327800-B1 6-PHENYLDIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS HEUMANN PHARMA GMBH & CO (DE) 1992-05-27 EP disclosed
US-5108998-A CARDIOTONIC THIADIAZINE DERIVATIVES HEUMANN PHARMA GMBH & CO. (DE) 1992-04-28 US disclosed
EP-0399196-A1 Diazine derivatives, process for their preparation, and medicaments containing these compounds HEUMANN PHARMA GMBH & CO (DE) 1990-11-28 EP disclosed
US-4954501-A INOTROPIC AGENTS HEUMANN PHARMA GMBH & CO. (DE) 1990-09-04 US disclosed
EP-0327800-A2 6-Phenyldihydro-3(2H)-pyridazinones, process for their preparation and medicines containing these compounds HEUMANN PHARMA GMBH & CO (DE) 1989-08-16 EP disclosed
US-4291042-A ANTIINFLAMMATORY AGENTS, ANTICONVULSANTS, ANTIARRHYTHMIA AGENTS JOHN WYETH & BROTHER LIMITED (GB) 1981-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152259-A1 HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR F12, F10, F11 CYP1A2 553/4885ALDH1A1 2302/4885TSHR 1331/4885
US-20050119250-A1 Antiproliferative agents HDAC1, HDAC11, MKI67 CYP1A2 3694/4885ALDH1A1 1033/4885TSHR 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.